Protagonist Therapeutics Inc PTGX shares are trading lower by 9.68% to $19.46 Wednesday morning after the company announced pricing of a $100 million public offering of shares of common stock.
What Else?
The underwritten public offering is for 5 million shares of its common stock at a public offering price of $20.00 per share.
The offering is expected to close on or about April 10, 2023, subject to customary closing conditions.
See Also: What's Going On With Aurinia Pharmaceuticals Stock Wednesday?
Protagonist intends to use the net proceeds from this offering to fund continued clinical development and pre-commercialization activities associated with rusfertide and for working capital and general corporate purposes.
According to data from Benzinga Pro, PTGX has a 52-week high of $25.76 and a 52-week low of $6.91.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
